Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

A randomized, placebo-controlled pilot trial of the delta opioid receptor agonist AZD2327 in anxious depression.

Richards EM, Mathews DC, Luckenbaugh DA, Ionescu DF, Machado-Vieira R, Niciu MJ, Duncan WC, Nolan NM, Franco-Chaves JA, Hudzik T, Maciag C, Li S, Cross A, Smith MA, Zarate CA Jr.

Psychopharmacology (Berl). 2016 Mar;233(6):1119-30. doi: 10.1007/s00213-015-4195-4. Epub 2016 Jan 4.

2.

Biomarkers in mood disorders research: developing new and improved therapeutics.

Niciu MJ, Mathews DC, Ionescu DF, Richards EM, Furey ML, Yuan P, Nugent AC, Henter ID, Machado-Vieira R, Zarate CA Jr.

Rev Psiquiatr Clin. 2014;41(5):131-134.

3.

Developing biomarkers in mood disorders research through the use of rapid-acting antidepressants.

Niciu MJ, Mathews DC, Nugent AC, Ionescu DF, Furey ML, Richards EM, Machado-Vieira R, Zarate CA Jr.

Depress Anxiety. 2014 Apr;31(4):297-307. doi: 10.1002/da.22224. Epub 2013 Dec 18. Review.

4.

NEUROBIOLOGICAL ASPECTS OF SUICIDE AND SUICIDE ATTEMPTS IN BIPOLAR DISORDER.

Mathews DC, Richards EM, Niciu MJ, Ionescu DF, Rasimas JJ, Zarate CA Jr.

Transl Neurosci. 2013 Jun;4(2). doi: 10.2478/s13380-013-0120-7.

5.

Current status of ketamine and related compounds for depression.

Mathews DC, Zarate CA Jr.

J Clin Psychiatry. 2013 May;74(5):516-7. doi: 10.4088/JCP.13ac08382. Review. No abstract available.

6.

Subanesthetic dose ketamine does not induce an affective switch in three independent samples of treatment-resistant major depression.

Niciu MJ, Luckenbaugh DA, Ionescu DF, Mathews DC, Richards EM, Zarate CA Jr.

Biol Psychiatry. 2013 Nov 15;74(10):e23-4. doi: 10.1016/j.biopsych.2013.01.038. Epub 2013 May 28. No abstract available.

7.

Neurobiology of anxious depression: a review.

Ionescu DF, Niciu MJ, Mathews DC, Richards EM, Zarate CA Jr.

Depress Anxiety. 2013 Apr;30(4):374-85. doi: 10.1002/da.22095. Epub 2013 Mar 11. Review.

8.

Second messenger/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part II: bipolar disorder.

Niciu MJ, Ionescu DF, Mathews DC, Richards EM, Zarate CA Jr.

CNS Spectr. 2013 Oct;18(5):242-51. doi: 10.1017/S1092852913000138. Epub 2013 Mar 11. Review.

9.

Second messenger/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part I: major depressive disorder.

Niciu MJ, Ionescu DF, Mathews DC, Richards EM, Zarate CA Jr.

CNS Spectr. 2013 Oct;18(5):231-41. doi: 10.1017/S1092852913000059. Epub 2013 Mar 5. Review.

10.

Human biomarkers of rapid antidepressant effects.

Zarate CA Jr, Mathews DC, Furey ML.

Biol Psychiatry. 2013 Jun 15;73(12):1142-55. doi: 10.1016/j.biopsych.2012.11.031. Epub 2013 Jan 29. Review.

11.

Acute stress symptoms do not worsen in posttraumatic stress disorder and abuse with a single subanesthetic dose of ketamine.

Zeng MC, Niciu MJ, Luckenbaugh DA, Ionescu DF, Mathews DC, Richards EM, Franco-Chaves J, Brutsche NE, Zarate CA Jr.

Biol Psychiatry. 2013 Jun 15;73(12):e37-8. doi: 10.1016/j.biopsych.2012.10.017. Epub 2012 Dec 13. No abstract available.

PMID:
23245747
12.

A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression.

Zarate CA Jr, Mathews D, Ibrahim L, Chaves JF, Marquardt C, Ukoh I, Jolkovsky L, Brutsche NE, Smith MA, Luckenbaugh DA.

Biol Psychiatry. 2013 Aug 15;74(4):257-64. doi: 10.1016/j.biopsych.2012.10.019. Epub 2012 Dec 1.

13.

Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression.

Luckenbaugh DA, Ibrahim L, Brutsche N, Franco-Chaves J, Mathews D, Marquardt CA, Cassarly C, Zarate CA Jr.

Bipolar Disord. 2012 Dec;14(8):880-7. doi: 10.1111/bdi.12003. Epub 2012 Sep 14.

14.

Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients.

Laje G, Lally N, Mathews D, Brutsche N, Chemerinski A, Akula N, Kelmendi B, Simen A, McMahon FJ, Sanacora G, Zarate C Jr.

Biol Psychiatry. 2012 Dec 1;72(11):e27-8. doi: 10.1016/j.biopsych.2012.05.031. Epub 2012 Jul 6. No abstract available.

15.

Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date.

Mathews DC, Henter ID, Zarate CA.

Drugs. 2012 Jul 9;72(10):1313-33. doi: 10.2165/11633130-000000000-00000. Review.

Supplemental Content

Loading ...
Support Center